ImmunityBio (IBRX) is back in focus after US regulators challenged promotional claims for its cancer drug Anktiva and a series of shareholder lawsuits followed, even as the company reported preliminary first quarter net product revenue of about US$44.2 million.

Recent headlines around the FDA warning letter and multiple class action filings have injected more volatility into ImmunityBio’s share price. The stock currently shows a 90 day share price return of 221.03% and a 1 year total shareholder return of 204.06%, while the 5 year total shareholder return of a 56.66% loss highlights how recent momentum contrasts with a weaker long term record.

If regulatory risk in ImmunityBio has you reassessing exposure to this theme, it may be worth scanning other names benefiting from healthcare and AI tailwinds through our 36 healthcare AI stocks

With ImmunityBio now trading at US$7.48, sitting at a large discount to a US$14.80 analyst target and with an intrinsic value estimate implying around 79% upside, investors are left asking: is this a genuine opportunity, or is the market already baking in future growth?

Most Popular Narrative: 44.6% Undervalued

Against the current share price of $7.48, the most followed narrative pegs ImmunityBio’s fair value at $13.50, creating a wide valuation gap that rests on ambitious growth and profitability assumptions.

The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.

Want to see what sits behind that confidence gap? This narrative leans on steep revenue expansion, a sharp margin swing and a premium future earnings multiple. Curious which assumptions really carry the weight here?

Result: Fair Value of $13.50 (UNDERVALUED)

However, this hinges on ANKTIVA expanding beyond bladder cancer and regulators accepting ImmunityBio’s trial designs, and either setback could quickly narrow that valuation gap.

Next Steps

With sentiment split between regulatory concerns and growth hopes, it makes sense to move quickly, review the data for yourself, and weigh up the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If ImmunityBio has sparked fresh questions about where to put your money to work next, do not stop here. Broaden your watchlist with targeted ideas built from data driven filters.

• Target potential bargains by scanning for companies that pair quality fundamentals with attractive pricing through the 62 high quality undervalued stocks.
• Prioritise resilience by checking out the 73 resilient stocks with low risk scores, focusing on businesses that score well on financial strength and risk metrics.
• Get ahead of the crowd with the screener containing 24 high quality undiscovered gems, highlighting companies with strong fundamentals that many investors may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.